Spera Pharma to Speak at Science & Technology Seminar 'Key Considerations for Quality Testing, Stability Testing, Specification Setting, and Impurity Separation, Analysis, and Management in Nucleic Acid Pharmaceuticals'

Kazuka Okada from the Development Analytical Research Institute at Spera Pharma Co., Ltd. (Headquarters: Osaka City, Osaka Prefecture; President and CEO: Keitaro Iwaki) will speak as an instructor at the seminar hosted by Science & Technology Co., Ltd., titled 'Key Considerations for Quality Testing, Stability Testing, Specification Setting, and Impurity Separation, Analysis, and Management in Nucleic Acid Pharmaceuticals'.

Event Overview

Seminar Title: Key Considerations for Quality Testing, Stability Testing, Specification Setting, and Impurity Separation, Analysis, and Management in Nucleic Acid Pharmaceuticals Date and Time: Live Streaming – August 31, 2026 (Monday), 13:00–17:00

Archive Streaming: September 15, 2026 (Tuesday) to October 1, 2026 (Thursday) Organizer: Science & Technology Co., Ltd. Details: https://www.science-t.com/seminar/C260827.html

Lecture Content

Session 1 (13:00–14:15): 'Key Considerations for Quality Testing, Stability Testing, and Specification Setting in Nucleic Acid Pharmaceuticals'

Speaker

Kazuka Okada

Spera Pharma Co., Ltd.

Scientist, Development Analytical Research Institute, Osaka Research Center

Purpose Nucleic acid pharmaceuticals possess unique characteristics distinct from conventional drugs, presenting specific challenges in quality testing, stability testing, and specification setting. This lecture will provide an integrated explanation—from quality assessment concepts to test design and specification setting—on how to design and organize these elements into a scientifically justifiable quality framework. Additionally, practical decision-making points for appropriately interpreting and explaining analytical results as quality attributes will also be introduced.

Program

Overview of Spera Pharma's Business

Overview and Characteristics of Nucleic Acid Pharmaceuticals

Quality Concepts and Key Considerations for Nucleic Acid Pharmaceuticals

Key Considerations in Stability Testing

Key Considerations in Specification Setting

Integration of Quality Design and Practical Considerations

Spera Pharma's Initiatives in Nucleic Acid Drug Development and Analytical Support as a CDMO

Q&A Session

Registration Please register using the button below.

Register

Company Overview: Spera Pharma Co., Ltd.

Company Name: Spera Pharma Co., Ltd. Headquarters: 2-17-85 Juso-Honmachi, Yodogawa-ku, Osaka City, Osaka Prefecture (Within Takeda Pharmaceutical Company Osaka Plant) Representative: President and CEO Keitaro Iwaki Founded: April 20, 2017 (Heisei 29) URL: https://www.spera-pharma.co.jp/ Business Activities: CMC research, development, and contract manufacturing services for pharmaceuticals

【Inquiries Regarding This Announcement】

Spera Pharma Co., Ltd. Inquiry Form

https://www.spera-pharma.co.jp/inquiry/